and the attached Exhibit 99.1 is being furnished and shall not be deemed “filed” for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that Section. The information in this

Chief Financial Officer — David House: David House was promoted to Chief Financial Officer.

Member of the Nominating and Corporate Governance Committee — Dr. Gilmer: Dr. Gilmer was appointed to the Nominating and Corporate Governance Committee with a specified cash retainer.

Entry into a Material Definitive Agreement. ​ On May 13, 2026, Armata Pharmaceuticals, Inc. (the “Company”) announced in the press release furnished hereto as Exhibit 99.1 that, on May 12, 2026, it had entered into, as borrower, a credit and security agreement (the “May 2026 Credit Agreement”) with Innoviva Strategic Opportunities LLC (“Innoviva”), a wholly owned subsidiary of Innoviva, Inc., a principal shareholder of the Company. The May 2026 Credit Agreement provides for a secured term loa…

Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant. ​ The disclosure set forth under

and the attached Exhibit 99.1 is being furnished and shall not be deemed “filed” for the purposes of Section 18 of the Securities and Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that Section. The information in this

Director — Dr. Daniel Gilmer: Dr. Daniel Gilmer was appointed as a new director of the company.

Results of Operations and Financial Condition. ​ On March 25, 2026, Armata Pharmaceuticals, Inc. announced its financial results for the three months and full fiscal year ended December 31, 2025, in the press release furnished hereto as Exhibit 99.1. ​ The information in this

Entry into a Material Definitive Agreement Amendments to Existing Credit Agreements On January 23, 2026, Armata Pharmaceuticals, Inc. (the “Company”) entered into amendments (collectively, the “Credit Agreement Amendments”) to four existing credit agreements, each as previously amended, with Innoviva Strategic Opportunities LLC (“Innoviva Sub”), a wholly owned subsidiary of Innoviva, Inc., a principal shareholder of the Company (“Innoviva”). The Credit Agreement Amendments extend the maturity…

Entry into a Material Definitive Agreement. On December 1, 2025, Armata Pharmaceuticals, Inc. (the “Company”) entered into a Capital on Demand™ Sales Agreement (the “Sales Agreement”) with JonesTrading Institutional Services LLC (“Jones”) with respect to an at the market offering program under which the Company may offer and sell, from time to time at its sole discretion, shares of its common stock, par value $0.01 per share (the “Common Stock”), having an aggregate offering price of up to $1…

Results of Operations and Financial Condition. ​ On November 12, 2025, the Company announced its financial results for the three and nine months ended September 30, 2025, in the press release furnished hereto as Exhibit 99.1. ​ The information in this

Entry into a Material Definitive Agreement. On August 12, 2025, Armata Pharmaceuticals, Inc. (the “Company”) announced in the press release furnished hereto as Exhibit 99.1 that, on August 11, 2025, it had entered into, as borrower, a credit and security agreement (the “August 2025 Credit Agreement”) with Innoviva Strategic Opportunities LLC (“Innoviva”), a wholly owned subsidiary of Innoviva, Inc., a principal shareholder of the Company. The August 2025 Credit Agreement provides for a secure…

and the attached Exhibit 99.1 is being furnished and shall not be deemed “filed” for the purposes of Section 18 of the Securities and Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that Section. The information in this

Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant. ​ The disclosure set forth under

Results of Operations and Financial Condition. ​ On May 14, 2025, Armata Pharmaceuticals, Inc. (the “Company”) announced its financial results for the three months ended March 31, 2025, in the press release furnished hereto as Exhibit 99.1. ​ The information in this

Results of Operations and Financial Condition. ​ On March 20, 2025, Armata Pharmaceuticals, Inc. (the “Company”) announced its financial results for the three months and full fiscal year ended December 31, 2024, in the press release furnished hereto as Exhibit 99.1. ​ The information in this

Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant. The disclosure set forth under

Entry into a Material Definitive Agreement. On March 12, 2025, Armata Pharmaceuticals, Inc. (the “Company”) announced in the press release furnished hereto as Exhibit 99.1 that, on March 12, 2025, it had entered into, as borrower, a credit and security agreement (the “March 2025 Credit Agreement”) with Innoviva Strategic Opportunities LLC (“Innoviva”), a wholly owned subsidiary of Innoviva, Inc., a principal shareholder of the Company. The March 2025 Credit Agreement provides for a secured te…

Chief Medical Officer — Mina Pastagia, M.D.: Dr. Pastagia's employment was concluded effective November 13, 2024.

Chief Medical Officer — Mina Pastagia, M.D.: The company terminated the employment of Dr. Pastagia as Chief Medical Officer.

Entry into a Material Definitive Agreement. On November 12, 2024, the Company entered into amendments to (i) that certain credit and security agreement (as amended, the “Credit Agreement”), dated as of July 10, 2023, by and among the Company, as borrower, Innoviva Strategic Opportunities LLC (“Innoviva”), as lender, and certain domestic subsidiaries of the Company, as guarantors (the “Second Amendment to Credit Agreement”) and (ii) that certain convertible credit and security agreement (as am…

Results of Operations and Financial Condition. ​ On November 13, 2024, Armata Pharmaceuticals, Inc. (the “Company”) announced its financial results for the three and nine months ended September 30, 2024, in the press release furnished hereto as Exhibit 99.1. ​ The information in this

Vice President, Corporate Controller — Richard Rychlik: Mr. Rychlik's employment concluded with a separation agreement.

Vice President, Corporate Controller — Richard Rychlik: Mr. Rychlik's employment will conclude effective as of September 30, 2024.

Senior Vice President, Finance — David House: The company hired a new Senior Vice President, Finance from an external candidate.